|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:annualReport
|
https://www.gsk.com/en-gb/investors/annual-report/
|
|
gptkbp:awards
|
Access to Medicine Index leader
|
|
gptkbp:CEO
|
gptkb:Emma_Walmsley
|
|
gptkbp:country
|
gptkb:United_Kingdom
|
|
gptkbp:divested
|
consumer healthcare division (Haleon, 2022)
|
|
gptkbp:founded
|
2000
|
|
gptkbp:foundedBy
|
merger of Glaxo Wellcome and SmithKline Beecham
|
|
gptkbp:headquartersLocation
|
gptkb:Brentford,_London,_England,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GlaxoSmithKline plc
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
consumer healthcare
|
|
gptkbp:ISIN
|
GB0009252882
|
|
gptkbp:keyPerson
|
gptkb:Emma_Walmsley
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:logo
|
https://www.gsk.com/media/7427/gsk-logo.png
|
|
gptkbp:marketCap
|
£60+ billion (2023)
|
|
gptkbp:memberOf
|
gptkb:FTSE_100_Index
gptkb:Pharmaceutical_Research_and_Manufacturers_of_America
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
£4.6 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Nicorette
gptkb:Polident
gptkb:Aquafresh
gptkb:Sensodyne
gptkb:Advair
gptkb:Augmentin
gptkb:Horlicks
gptkb:Pandemrix
gptkb:Shingrix
gptkb:Ventolin
gptkb:Panadol
gptkb:Voltaren
|
|
gptkbp:numberOfEmployees
|
~70,000
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:predecessor
|
gptkb:Glaxo_Wellcome
gptkb:SmithKline_Beecham
|
|
gptkbp:products
|
vaccines
pharmaceutical drugs
consumer healthcare products
|
|
gptkbp:researchInterest
|
gptkb:HIV/AIDS
immunology
infectious diseases
oncology
respiratory diseases
|
|
gptkbp:revenue
|
£29.3 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:London_Stock_Exchange
gptkb:New_York_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:GSK
|
|
gptkbp:subsidiary
|
gptkb:Stiefel_Laboratories
gptkb:ViiV_Healthcare
|
|
gptkbp:website
|
https://www.gsk.com/
|
|
gptkbp:bfsParent
|
gptkb:GSK
gptkb:GSK_India
|
|
gptkbp:bfsLayer
|
6
|